News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,508 Results
Type
Article (41218)
Company Profile (289)
Press Release (656001)
Section
Business (206161)
Career Advice (2083)
Deals (35633)
Drug Delivery (103)
Drug Development (81949)
Employer Resources (169)
FDA (16364)
Job Trends (15089)
News (349022)
Policy (33447)
Tag
Academia (2608)
Alliances (49937)
Alzheimer's disease (1288)
Approvals (16309)
Artificial intelligence (148)
Bankruptcy (358)
Best Places to Work (11714)
Biotechnology (204)
Breast cancer (189)
Cancer (1394)
Cardiovascular disease (116)
Career advice (1738)
Cell therapy (289)
Clinical research (65466)
Collaboration (496)
Compensation (260)
COVID-19 (2604)
C-suite (108)
Data (1400)
Diabetes (185)
Diagnostics (6227)
Earnings (85518)
Employer resources (147)
Events (111340)
Executive appointments (395)
FDA (17047)
Funding (430)
Gene therapy (206)
GLP-1 (678)
Government (4673)
Healthcare (19039)
Infectious disease (2702)
Inflammatory bowel disease (115)
Interviews (333)
IPO (16422)
Job creations (3778)
Job search strategy (1477)
Layoffs (439)
Legal (8051)
Lung cancer (203)
Lymphoma (99)
Manufacturing (215)
Medical device (13407)
Medtech (13412)
Mergers & acquisitions (19363)
Metabolic disorders (513)
Neuroscience (1624)
NextGen Class of 2024 (6627)
Non-profit (4577)
Northern California (1700)
Obesity (296)
Opinion (201)
Patents (118)
People (57059)
Phase I (20322)
Phase II (28791)
Phase III (21566)
Pipeline (520)
Postmarket research (2614)
Preclinical (8656)
Radiopharmaceuticals (238)
Rare diseases (268)
Real estate (5962)
Regulatory (22193)
Research institute (2360)
Resumes & cover letters (359)
Southern California (1468)
Startups (3614)
United States (15251)
Vaccines (592)
Weight loss (229)
Date
Last 7 days (590)
Last 30 days (2282)
Last 365 days (35557)
2024 (35398)
2023 (40444)
2022 (51622)
2021 (56260)
2020 (54760)
2019 (47417)
2018 (35724)
2017 (32582)
2016 (32089)
2015 (38127)
2014 (31806)
2013 (26776)
2012 (28973)
2011 (29659)
2010 (27723)
Location
Africa (749)
Arizona (199)
Asia (37909)
Australia (6260)
California (3830)
Canada (1460)
China (308)
Colorado (171)
Connecticut (178)
Europe (81666)
Florida (535)
Georgia (135)
Illinois (392)
Indiana (229)
Maryland (632)
Massachusetts (2981)
Michigan (173)
Minnesota (293)
New Jersey (1107)
New York (1085)
North Carolina (750)
Northern California (1700)
Ohio (146)
Pennsylvania (926)
South America (1122)
Southern California (1468)
Texas (550)
Utah (108)
Washington State (401)
697,508 Results for "eli lilly canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
A week after dining with Trump and his team at Mar-a-Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration on key issues affecting the pharma industry.
December 12, 2024
·
2 min read
·
Tristan Manalac
Editorial
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.
November 1, 2024
·
3 min read
·
Greg Slabodkin
Drug shortages
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded pharmacies are still making them. That’s unprecedented.
November 26, 2024
·
4 min read
·
Ben Hargreaves
Career Pathing
From Eli Lilly to Entrepreneur: A Journey to Independent Consulting
After more than 20 years at Eli Lilly, Leslie Sam moved into independent consulting. To prepare for the transition, she focused on becoming technically deep and earning industry recognition.
July 31, 2024
·
4 min read
·
Angela Gabriel
Manufacturing
Lilly Pumps $3B Into Wisconsin Site as Compounders Close In on Tirzepatide
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to challenge an FDA decision to formally end the shortage of the obesity and diabetes drug.
December 6, 2024
·
2 min read
·
Tristan Manalac
Drug shortages
Lilly’s Tirzepatide Could Land Again on FDA Drug Shortage List, Opens Door for Compounders
While the regulator conducts another review into the supply of Eli Lilly’s tirzepatide, compounders will be able to continue selling their own remixed versions of the blockbuster drug.
October 14, 2024
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs
Eli Lilly CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as biotechs press on with compelling data.
October 9, 2024
·
3 min read
·
Annalee Armstrong
GLP-1
Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment
Eli Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the activin type IIA receptor to induce weight loss and boost muscle mass.
November 21, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Lilly Lowers Brain Swelling With Modified Dosing of Alzheimer’s Drug Kisunla
Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain swelling of patients in a late-stage trial following an adjusted dosing regimen.
October 30, 2024
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting better long-term outcomes than Johnson & Johnson’s blockbuster therapy Stelara.
October 15, 2024
·
2 min read
·
Tristan Manalac
1 of 69,751
Next
